HRQoL and survival data were compared between 10-day decitabine 20 mg/m2 and daunorubicin 60 mg/m2 for 3 days and 7 days of cytarabine 100 mg/m2 (3 + 7). Similar survival and allo-HSCT rates between treatment groups are depicted on the left. The risk of HRQoL deterioration was lower in the decitabine group than in the 3 + 7 treatment group (on the right) at 2 months.
